Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Short-term Investments: 2014-2020

Historic Short-term Investments for Fortress Biotech (FBIO) over the last 5 years, with Dec 2020 value amounting to $76.8 million.

  • Fortress Biotech's Short-term Investments rose 412.00% to $76.8 million in Q4 2020 from the same period last year, while for Dec 2020 it was $76.8 million, marking a year-over-year increase of 412.00%. This contributed to the annual value of $76.8 million for FY2020, which is 412.00% up from last year.
  • Latest data reveals that Fortress Biotech reported Short-term Investments of $76.8 million as of Q4 2020, which was up 412.00% from $15.0 million recorded in Q4 2019.
  • In the past 5 years, Fortress Biotech's Short-term Investments ranged from a high of $76.8 million in Q4 2020 and a low of $5.0 million during Q2 2019.
  • Moreover, its 3-year median value for Short-term Investments was $17.6 million (2018), whereas its average is $25.4 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first plummeted by 86.37% in 2019, then soared by 412.00% in 2020.
  • Fortress Biotech's Short-term Investments (Quarterly) stood at $36.0 million in 2017, then tumbled by 51.10% to $17.6 million in 2018, then dropped by 14.79% to $15.0 million in 2019, then spiked by 412.00% to $76.8 million in 2020.
  • Its last three reported values are $76.8 million in Q4 2020, $15.0 million for Q4 2019, and $14.9 million during Q3 2019.